JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

Jazz Pharmaceuticals (JAZZ) announced that a mid-stage study evaluating the efficacy and safety of its investigational candidate, suvecaltamide (JZP385), in adult patients with essential tremor (ET) did not meet its primary endpoint. The study also failed to achieve statistical significance on the key secondary endpoint of the Clinical Global Impression-Severity scale, which is a measure of the severity of illness compared with placebo at week 12. Jazz's shares lost 4.7% during trading hours on Jun 20, afte ...